Ensuiko Sugar Refining Co., Ltd.
2112・Standard Market・Foods
Business
Ensuiko Sugar Refining is an independent sugar refiner founded in 1904, operating a sugar business centered on the manufacture and sale of sugar (approximately 95% of net sales), a bio business centered on lactosucrose oligosaccharide and cyclodextrin, and other businesses including real estate leasing. Sugar products are manufactured through processing consignments to Taiheiyo Seito and Kansai Seito, and sold by subsidiary Pearl Ace Co., Ltd. under the "Pearl Ace" brand. In the bio business, the "Oligo no Okage" series has captured demand for gut health as a Food for Specified Health Uses (FOSHU), and a new product, "Beets no Okage," was launched in February 2026. Major customers are commercial users such as food manufacturers, restaurants, and retailers, as well as general consumers, with Terrato Corporation being the largest customer, accounting for 11.5% of sales.
Business Model
The company does not own its own factories, and instead controls manufacturing costs through contract processing arrangements with Taiheiyo Seito and Kansai Seito, as well as a joint production framework with other industry players. Sales are handled by its subsidiary Pearl Ace, while raw material supply is secured through a raw sugar procurement contract with Mitsubishi Corporation and a supply agreement with Nansei Sugar. Built on the stable earnings base of the sugar business, the company's structure is characterized by a two-layer model in which it also accumulates direct-sales revenue from high-value-added bio-products via e-commerce and social media.
Company Strengths
Without owning its own factories, the company has operated a joint production system since 2001, outsourcing processing to Pacific Sugar and Kansai Sugar while collaborating with multiple sugar refining companies. By containing fixed manufacturing costs, the sugar business segment's profit margin improved from 12.5% to 13.4%, and segment profit for FY2026 (ending March 2026) reached a record high of ¥4,193 million.
The "Oligo no Okage" series, which began nationwide sales in 1994 and obtained Foods for Specified Health Uses (FOSHU) labeling approval in 1995, has built a base of brand recognition amid the gut-health boom. Having marked its 30th anniversary since launch in 2024, core-user-oriented products such as large-capacity formats have performed solidly. The bio business secured net sales of ¥1,603 million and segment profit of ¥282 million.
The company formed a business alliance with Daito Sugar in July 2023, and in October 2025 concluded a comprehensive alliance with Fuji Nihon covering manufacturing, purchasing, logistics, and R&D. It is advancing cost reductions and CO2 emission cuts through joint production and purchasing, as well as joint development of new materials and products in the bio field, building a cross-industry collaborative framework as an independent sugar refining company.
ENVALITH's Perspective
Performance Trend
Revenue increased 31% over five fiscal periods, from ¥25,134 million in FY2022 (ended March 2022) to ¥32,982 million in FY2026 (ending March 2026). Operating profit expanded approximately 3.8-fold over the same period, from ¥807 million to ¥3,047 million, with the operating margin sharply improving from 3.2% to 9.2%. In FY2026 (ending March 2026), revenue growth was limited to 1.4%, while net income rose 29.4% to ¥2,765 million, reflecting a marked improvement in profitability. As an external factor, the decline in overseas raw sugar prices (15.52 cents at period-end) held down procurement costs, while demand related to the Osaka Expo and inbound tourism boosted commercial-use sales. However, for FY2027 (ending March 2027), the company forecasts a substantial decline in profit, reflecting a sugar price reduction and a downward trend in demand.
Growth Strategy
Aiming for sustainable enhancement of corporate value by maintaining the earnings base of the sugar business and diversifying through the bio business
On May 8, 2026, the company disclosed its medium-term management plan covering the period from FY2026 (ending March 2026) to FY2031 (ending March 2031). It aims to achieve sustainable enhancement of corporate value by steadily implementing measures to secure stable earnings in the sugar business and diversify its revenue base centered on the bio business (oligosaccharides and beets).
Based on the agreement concluded in October 2025, the company is pursuing cost and CO2 reductions through joint production, purchasing, and logistics efficiency improvements in the refined sugar field, as well as joint development of new materials and products in the bio field leveraging the strengths of both companies. Discussions by the project team are currently ongoing.
The company is strengthening its approach to diverse customer segments, including beauty-conscious consumers, through the "Oligo no Okage" series. It is also capturing natural-oriented consumers with "Satokibi Oligo" (sugarcane oligosaccharide). Following the renewal of "Beets no Okage," sales expansion is being driven mainly through the e-commerce site, with the aim of growing it into a third pillar of earnings.
In response to declining sugar consumption due to the rise of high-intensity sweeteners and population decline, the company is working to curb the decline in consumption by promoting accurate knowledge about sugar. It has already implemented a price revision (price cut) for the first time in about seven years, and continues to focus on thorough cost management and sales at appropriate prices to revitalize the market.
Centered on four pillars—"new business and new product development," "strengthening of existing businesses," "strengthening of sales structure," and "social contribution activities"—the company is deepening collaborative arrangements that leverage both companies' sales networks. Collaboration is being strengthened, including an executive taking on the role of councilor for "Clover Smiles Act" and jointly hosting beach cleanup activities.
Last updated: July 19, 2026